

CITATION REPORT

List of articles citing

Subaortic obstruction after sildenafil in a patient with hypertrophic cardiomyopathy

DOI: 10.1056/nejm199908263410916

New England Journal of Medicine, 1999, 341, 700-1.

Source: <https://exaly.com/paper-pdf/30876570/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
29	Warfarin interaction. <i>Reactions Weekly</i> , 1999 , &NA;, 12	0	
28	Safety of sildenafil. <i>Current Opinion in Urology</i> , 2000 , 10, 613-5	2.8	2
27	Sildenafil citrate: a therapeutic update. <i>Clinical Therapeutics</i> , 2001 , 23, 2-23	3.5	65
26	Drugs acting on the cerebral and peripheral circulations. <i>Side Effects of Drugs Annual</i> , 2001 , 229-232	0.2	
25	Reply. <i>BJU International</i> , 2001 , 87, 907-909	5.6	
24	Effects of sildenafil (viagra) on human myocardial contractility, in vitro arrhythmias, and tension of internal mammaria arteries and saphenous veins. <i>Journal of Cardiovascular Pharmacology</i> , 2003 , 41, 734-743	2.1	42
23	Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications. <i>The American Journal of Geriatric Cardiology</i> , 2004 , 13, 332-5		
22	Advances in the Treatment of Erectile Dysfunction: A Focus on Tadalafil. <i>Journal of Pharmacy Practice</i> , 2004 , 17, 239-250	1.3	1
21	Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. <i>Acta Pharmacologica Sinica</i> , 2009 , 30, 1-24	8	45
20	Stress Imaging in Men with Hypertrophic Cardiomyopathy and Erectile Dysfunction. <i>Journal of Men's Health</i> , 2013 , 10, 152-153	1.2	1
19	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2014 , 35, 2733-79	9.5	2361
18	Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2015 , 116, 618-21	3	3
17	Triptans. 2016 , 205-210		
16	Calcium channel blockers. 2016 , 23-39		
15	Hypertrophic Cardiomyopathy. 2017 , 113-136		
14	Hypertrophic cardiomyopathy: an updated review on diagnosis, prognosis, and treatment. <i>Heart Failure Reviews</i> , 2019 , 24, 439-459	5	25
13	Lifestyle Modification: Diet, Exercise, Sports, and Other Issues. 2019 , 169-182		

12 Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Diagnosis, Clinical Course and Therapy.

11 Preintervention imaging and intraoperative management care of the hypertrophic obstructive cardiomyopathy patient. *Asian Cardiovascular and Thoracic Annals*, **2021**, 2184923211047126 o.6

10 Therapie. **2002**, 129-246

9 Miocardiopatĳ hipertrĳica. **2006**, 128-134

8 Sildenafil. **2006**, 3133-3137

7 Triptans. **2006**, 3525-3528

6 DRUGS THAT ACT ON THE CEREBRAL AND PERIPHERAL ARTERIAL AND VENOUS CIRCULATIONS. **2009**, 431-448

5 Drugs Used to Treat Hypertension, Heart Failure, and Angina Pectoris. **2009**, 1-196

4 Hypertrophic Cardiomyopathy. **2010**, 155-160

3 Lifestyle Modification: Diet, Exercise, Sports and Other Issues. **2015**, 143-154

2 Phosphodiesterase type V inhibitors. **2016**, 734-742

1 Outcomes and Complications of alcohol septal ablation for younger patients with hypertrophic obstructive cardiomyopathy: a single-centre study. *Intervencni A Akutni Kardiologie*, **2021**, 20, 182-189 o